Seattle Genetics, Inc. (SGEN) recently commenced a phase II study of Adcetris in combination with the current standard of care in treatment-naive patients with diffuse large B-cell lymphoma (:DLBCL).
The open-label, phase II study will evaluate roughly 50 frontline high-risk DLBCL patients, who will receive Adcetris in combination with Rituxan and standard chemotherapy (R-CHOP).
The primary endpoint is to evaluate the complete remission rate and safety of the A+RCHOP regimen. Secondary endpoints include objective response rate, progression-free survival and overall survival.
This study will generate tolerability data as well as antitumor activity data achieved by Adcetris plus the current standard frontline regimen.
In Jun 2013, Seattle Genetics had presented data at the International Conference on Malignant Lymphoma (:ICML) from a phase II study of Adcetrisin patients with relapsed B-cell lymphomas. The study involved 44 patients including 25 DLBCL patients who achieved an objective response rate of 44%.
Seattle Genetics’ sole marketed antibody-drug conjugate (ADC) product is Adcetris. Adcetris is used for the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris is also approved for the treatment of systemic anaplastic large cell lymphoma after failure of at least one multi-agent chemotherapy regimen.
ADCs have lately been attracting a lot of interest with major companies entering into collaborations. Seattle Genetics has an alliance with Genentech, a business wing of Roche Holding AG (RHHBY), for the development of ADCs.
More From Zacks.com